Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos M de Castro

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Cancer|June 22, 2010
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionMeletios Dimopoulos, Adrian Alegre, Edward A Stadtmauer, et al.
Cancer Investigation|February 15, 2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myelomaLauren A Held, David Rizzieri, Gwynn D Long, et al.
Nutrition Research (New York, N.Y.)|September 12, 2014
Apolipoprotein E knockout mice have accentuated malnutrition with mucosal disruption and blunted insulin-like growth factor I responses to refeedingReinaldo B Oriá, Carlos Meton G Vieira, Relana C Pinkerton, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Blood Advances|April 26, 2024
Modified Delphi panel consensus recommendations for management of severe aplastic anemiaDaria V Babushok, Amy E DeZern, Carlos M de Castro, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myelomaCristina Gasparetto, Jon P Gockerman, Louis F Diehl, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Blood|August 17, 2011
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetDale J Christensen, Youwei Chen, Jessica Oddo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
AIDS Research and Human Retroviruses|October 28, 2006
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM)Carlos M De Castro-Costa, Abelardo Q C Araújo, Márcio M Barreto, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cancer|June 22, 2010
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionMeletios Dimopoulos, Adrian Alegre, Edward A Stadtmauer, et al.
Cancer Investigation|February 15, 2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myelomaLauren A Held, David Rizzieri, Gwynn D Long, et al.
Nutrition Research (New York, N.Y.)|September 12, 2014
Apolipoprotein E knockout mice have accentuated malnutrition with mucosal disruption and blunted insulin-like growth factor I responses to refeedingReinaldo B Oriá, Carlos Meton G Vieira, Relana C Pinkerton, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Blood Advances|April 26, 2024
Modified Delphi panel consensus recommendations for management of severe aplastic anemiaDaria V Babushok, Amy E DeZern, Carlos M de Castro, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myelomaCristina Gasparetto, Jon P Gockerman, Louis F Diehl, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Blood|August 17, 2011
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetDale J Christensen, Youwei Chen, Jessica Oddo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
AIDS Research and Human Retroviruses|October 28, 2006
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM)Carlos M De Castro-Costa, Abelardo Q C Araújo, Márcio M Barreto, et al.
Pageof 3